HSBC Holdings
VKTX icon

HSBC Holdings’s Viking Therapeutics VKTX Stock Holding History

HSBC Holdings’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,200
Closed -$360K – 3248
2025
Q4 		$360K Buy
+10,200
New +$361K ﹤0.01% 2448

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

HSBC Holdings's VKTX Position: Q1 2026 in Review

HSBC Holdings increased its Viking Therapeutics (VKTX) stake by 47% in Q1 2026, buying an estimated $186K and bringing the position to 18,119 shares worth $592K. The position accounts for ﹤0.01% of the portfolio, ranked #2149.

HSBC Holdings first reported a position in VKTX in Q1 2020 and has held it in 10 quarters since. The position peaked at $1.03M in Q3 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • HSBC Holdings held 18,119 shares of Viking Therapeutics worth $592K as of Q1 2026.
  • HSBC Holdings bought 5,772 Viking Therapeutics shares in Q1 2026, an estimated $186K.
  • Viking Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2149 holding.
  • HSBC Holdings first reported a position in Viking Therapeutics in Q1 2020 and has held it in 10 quarters since.
  • HSBC Holdings's Viking Therapeutics position peaked at $1.03M in Q3 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.